NCT04356690View on ClinicalTrials.gov

Etoposide in Patients With COVID-19 Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
COVID-19
Interventions
DRUG

Etoposide

Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4.

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Boston Medical Center

OTHER

NCT04356690 - Etoposide in Patients With COVID-19 Infection | Biotech Hunter | Biotech Hunter